Company intelligence / Profile preview

AMSbiopharma

Ownership: Private
Development stage: Commercial

Overview

AMSbiopharma is an advanced analytical CRO specializing in R&D support and quality control for the pharmaceutical, biopharmaceutical, and chemical industries. The company offers bioanalysis, metabolomics/lipidomics services using UPLC-MS/MS and ICP-MS technologies to support drug development from preclinical through clinical phases. It is recognized for precision analytics in small molecules as well as protein-, peptide-, mAb-, and nucleic acid-based drugs. AMSbiopharma is part of the AMSlab Group and has launched innovation initiatives to enhance service offerings in Europe[1][2][3][4].

Modalities: Small moleculeProteinPeptidesMonoclonal antibody
Industry: Contract Research Organization

Partnerships

Galician Innovation Agency – funding partner for innovation planGalicia Food Cluster/Clusaga – collaboration on dairy sector proteomics projectOther private/public R&D collaborations at regional/national/EU level

Beyond the preview

Go deeper on AMSbiopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMSbiopharma.

Explore the full profile